ALKEM Share Price Performance
₹0
-4818.15 (-100.00%)
Price ₹0
Fair Value₹6,913.00
Share Pricen/a
Alkem Laboratories Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
ALKEM Community Narratives
AN
Fair Value ₹6.91k 22.8% undervalued intrinsic discount
Rising Global Healthcare Demand And US CDMO Will Boost Generic Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹5.92k 9.9% undervalued intrinsic discount
Expanding Biosimilars And CDMO Will Open Global Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹4.68k 14.0% overvalued intrinsic discount
Rising Cost Pressures And Regulatory Risks Will Undercut Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Cost Pressures And Regulatory Risks Will Undercut Margins
Key Takeaways Intensifying pricing pressures, regulatory risks, and compliance costs threaten margins and growth, especially given Alkem's reliance on price-controlled markets and traditional sales channels. Escalating R&D, environmental, and operational expenses, combined with a limited product pipeline, increase the risk of stagnation and constrain long-term earnings potential.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹4.68k
14.0% overvalued intrinsic discount
Fair Value
Revenue
6.69% p.a.
Profit Margin
13.56%
Future PE
33.74x
Price in 2029
₹6.62k
Rising Global Healthcare Demand And US CDMO Will Boost Generic Markets
Key Takeaways Accelerating margin expansion, product leadership in domestic therapies, and global demand are set to drive sustained outperformance in revenue and profitability. Strategic R&D investments and successful facility ramp-up will diversify revenue streams and support premium valuation through biopharma and complex generic growth.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹6.91k
22.8% undervalued intrinsic discount
Fair Value
Revenue
12.89% p.a.
Profit Margin
16.48%
Future PE
34.65x
Price in 2029
₹9.79k
Expanding Biosimilars And CDMO Will Open Global Markets
Key Takeaways Strong positioning in high-growth therapies and international diversification, supported by R&D and new business initiatives, enhances revenue potential and margin resilience. Focus on expanding the branded portfolio and leveraging demographic trends underpins a visible pipeline for future earnings growth and operational improvement.Read more
36
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹5.92k
9.9% undervalued intrinsic discount
Fair Value
Revenue
9.79% p.a.
Profit Margin
14.16%
Future PE
38.81x
Price in 2028
₹8.45k
Trending Discussion
Recently Updated Narratives
AN
ALKEM: Rich P/E And Distant US Generic Launches Will Restrain Upside
Fair Value: ₹4.68k 14.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ALKEM: Long Dated US Settlements And Dermatology Launch Will Support ReRating
Fair Value: ₹6.91k 22.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ALKEM: Upcoming Product Launches And Board Review Will Influence Medium-Term Prospects
Fair Value: ₹5.92k 9.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alkem Laboratories Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 198.32
- 62.92%
- 16.64%
- 17.1%
About ALKEM
- Founded
- 1973
- Employees
- 18785
- CEO
- WebsiteView website
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
